Aurinia Pharmaceuticals, Inc. (AUP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ANI Pharmaceuticals, Inc.

Aurinia Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Twist Bioscience Corp.

Iovance Biotherapeutics, Inc.

Xencor, Inc.

Merus NV

Vir Biotechnology, Inc.

Maravai Lifesciences Holdings, Inc.

Summit Therapeutics, Inc.

Spyre Therapeutics, Inc.

Why is Aurinia Pharmaceuticals, Inc. ?

With a growth in Net Sales of 12.08%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 5 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 92.59 MM
ROCE(HY) Highest at 17.33%
INTEREST COVERAGE RATIO(Q) Highest at 3,071.35

With ROE of 16.33%, it has a fair valuation with a 3.16 Price to Book Value

Over the past year, while the stock has generated a return of 86.91%, its profits have risen by 202.3% ; the PEG ratio of the company is 0.1

High Institutional Holdings at 50.21%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 2.24% over the previous quarter.

Market Beating performance in long term as well as near term

Along with generating 86.91% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Aurinia Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aurinia Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Aurinia Pharmaceuticals, Inc.

72.99%

4.14

48.64%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

204.27%

EBIT Growth (5y)

23.31%

EBIT to Interest (avg)

-74.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.85

Sales to Capital Employed (avg)

0.52

Tax Ratio

4.69%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

50.21%

ROCE (avg)

19.90%

ROE (avg)

3.27%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.16

EV to EBIT

15.39

EV to EBITDA

11.23

EV to Capital Employed

15.32

EV to Sales

3.27

PEG Ratio

0.10

Dividend Yield

ROCE (Latest)

99.51%

ROE (Latest)

16.33%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 92.59 MM

ROCE(HY)

Highest at 17.33%

INTEREST COVERAGE RATIO(Q)

Highest at 3,071.35

RAW MATERIAL COST(Y)

Fallen by -6.5% (YoY

NET SALES(Q)

Highest at USD 70.01 MM

OPERATING PROFIT(Q)

Highest at USD 34.31 MM

PRE-TAX PROFIT(Q)

At USD 22.27 MM has Grown at 49.06%

NET PROFIT(Q)

At USD 21.62 MM has Grown at 51.24%

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Aurinia Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 92.59 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Interest Coverage Ratio

Highest at 3,071.35

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales

Highest at USD 70.01 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 34.31 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

At USD 22.27 MM has Grown at 49.06%

over average net sales of the previous four periods of USD 14.94 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 21.62 MM has Grown at 51.24%

over average net sales of the previous four periods of USD 14.3 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by -6.5% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales